A 45-year-old male patient with a 7-year history of moderate-to-severe plaque psoriasis presents to the pharmacy. He has previously tried methotrexate but discontinued due to intolerance. He is currently starting biologic therapy and is prescribed ustekinumab. The patient is concerned about the cost of treatment and asks about biosimilar options. His medical history is otherwise unremarkable, and he has no known drug allergies.

Based on the recent evidence comparing FYB202 biosimilar to reference ustekinumab, what is the most appropriate counseling point regarding the efficacy of FYB202 for this patient?

A 52-year-old female patient with moderate-to-severe plaque psoriasis has been receiving reference ustekinumab for 6 months with good clinical response. Due to insurance formulary changes, her provider plans to switch her to the biosimilar FYB202. The patient is worried about potential safety issues or loss of efficacy after switching.

What information should the pharmacist provide regarding the safety and immunogenicity of switching from reference ustekinumab to FYB202?

A 38-year-old male with moderate-to-severe plaque psoriasis is uninsured and expresses concern about the affordability of biologic treatments. He is considering starting ustekinumab therapy. The pharmacist is asked about the potential benefits of biosimilar options like FYB202.

Which statement best reflects the clinical and economic implications of prescribing FYB202 biosimilar for this patient?